PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies

British Journal of Haematology

Volumn 156, Issue 1, 2012, Pages 76-88

  Duhoux, Francois P ^a   Ameye, Geneviève ^a   Montano Almendras, Carmen P ^b   Bahloula, Khadija ^a   Mozziconacci, Marie J ^c   Laibe, Sophy ^c   Wlodarska, Iwona ^d   Michaux, Lucienne ^d   Talmant, Pascaline ^e   Richebourg, Steven ^e   Lippert, Eric ^f   Speleman, Frank ^g   Herens, Christian ^h   Struski, Stéphanie ⁱ   Raynaud, Sophie ^j   Auger, Nathalie ^k   Nadal, Nathalie ^l   Rack, Katrina ^m   Mugneret, Francine ⁿ   Tigaud, Isabelle ^o   Lafage, Marina ^p   Taviaux, Sylvie ^q   Roche Lestienne, Catherine ^r   Latinne, Dominique ^a   Libouton, Jeanne M ^a   Demoulin, Jean Baptiste ^b   Poirel, Hélène A ^a   more..

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b DE DUVE INSTITUTE   (Belgium)

^c INSTITUT PAOLI CALMETTES   (France)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f BORDEAUX UNIVERSITY HOSPITAL   (France)

^g GHENT UNIVERSITY HOSPITAL   (Belgium)

^h UNIVERSITY OF LIÈGE   (Belgium)

ⁱ CHU PURPAN   (France)

^j UNIVERSITY HOSPITAL OF NICE   (France)

^k INSTITUT GUSTAVE ROUSSY   (France)

^l HÔPITAL NORD   (France)

^m INSTITUTE OF PATHOLOGY AND GENETICS   (Belgium)

ⁿ DIJON UNIVERSITY HOSPITAL   (France)

^o CENTRE HOSPITALIER LYON SUD   (France)

^p TIMONE HOSPITAL   (France)

^q HÔPITAL ARNAUD DE VILLENEUVE   (France)

^r LILLE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

1p36; Acute myeloid leukaemia; Lymphoid malignancy; Myelodysplastic syndrome; PRDM16

Indexed keywords

PROTEIN IKZF1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETV6; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW; BONE MARROW CELL; CANCER SURVIVAL; CD34+ CELL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE EXPRESSION; GENE LOCUS; GENE REARRANGEMENT; GENE TRANSLOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MYELODYSPLASTIC SYNDROME; PRDM16 GENE; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CHILD; CHILD, PRESCHOOL; CHROMOSOME BANDING; CHROMOSOME BREAKPOINTS; CHROMOSOMES, HUMAN, PAIR 1; DNA-BINDING PROTEINS; FEMALE; GENE ORDER; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; ONCOGENE PROTEINS, FUSION; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC; YOUNG ADULT;

EID: 83555164871     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08918.x     Document Type: Article

References (53)

1. Aguilo, F., Avagyan, S., Labar, A., Sevilla, A., Lee, D.F., Kumar, P., Lemischka, I.R., Zhou, B.Y. & Snoeck, H.W. (2011) Prdm16 is a physiologic regulator of hematopoietic stem cells. Blood, 117, 5057-5066.
2. Barjesteh van Waalwijk van Doorn-Khosrovani, S., Erpelinck, C., Lowenberg, B. & Delwel, R. (2003) Low expression of MDS1-EVI1-like-1 (MEL1) and EVI1-like-1 (EL1) genes in favorable-risk acute myeloid leukemia. Experimental Hematology, 31, 1066-1072.
3. Beck, A.H., Lee, C.H., Witten, D.M., Gleason, B.C., Edris, B., Espinosa, I., Zhu, S., Li, R., Montgomery, K.D., Marinelli, R.J., Tibshirani, R., Hastie, T., Jablons, D.M., Rubin, B.P., Fletcher, C.D., West, R.B. & van de Rijn, M. (2010) Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling. Oncogene, 29, 845-854.
4. Beillard, E., Pallisgaard, N., van der Velden, V.H., Bi, W., Dee, R., van der Schoot, E., Delabesse, E., Macintyre, E., Gottardi, E., Saglio, G., Watzinger, F., Lion, T., van Dongen, J.J., Hokland, P. & Gabert, J. (2003) Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia, 17, 2474-2486.
5. Bene, M.C., Castoldi, G., Knapp, W., Ludwig, W.D., Matutes, E., Orfao, A. & van't Veer, M.B. (1995) Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia, 9, 1783-1786.
6. Bertrand, P., Bastard, C., Maingonnat, C., Jardin, F., Maisonneuve, C., Courel, M.N., Ruminy, P., Picquenot, J.M. & Tilly, H. (2007) Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. Leukemia, 21, 515-523.
7. Bjork, B.C., Turbe-Doan, A., Prysak, M., Herron, B.J. & Beier, D.R. (2010) Prdm16 is required for normal palatogenesis in mice. Human Molecular Genetics, 19, 774-789.
8. Bloomfield, C.D., Garson, O.M., Volin, L., Knuutila, S. & de la Chapelle, A. (1985) t(1;3)(p36;q21) in acute nonlymphocytic leukemia: a new cytogenetic-clinicopathologic association. Blood, 66, 1409-1413.
9. Bohlander, S.K. (2005) ETV6: a versatile player in leukemogenesis. Seminars in Cancer Biology, 15, 162-174.
10. Breems, D.A., Van Putten, W.L., De Greef, G.E., Van Zelderen-Bhola, S.L., Gerssen-Schoorl, K.B., Mellink, C.H., Nieuwint, A., Jotterand, M., Hagemeijer, A., Beverloo, H.B. & Lowenberg, B. (2008) Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. Journal of Clinical Oncology, 26, 4791-4797.
11. Chuikov, S., Levi, B.P., Smith, M.L. & Morrison, S.J. (2010) Prdm16 promotes stem cell maintenance in multiple tissues, partly by regulating oxidative stress. Nature Cell Biology, 12, 999-1006.
12. Couture, J.F., Dirk, L.M., Brunzelle, J.S., Houtz, R.L. & Trievel, R.C. (2008) Structural origins for the product specificity of SET domain protein methyltransferases. Proceedings of the National Academy of Sciences of the United States of America, 105, 20659-20664.
13. Deluche, L., Joha, S., Corm, S., Daudignon, A., Geffroy, S., Quief, S., Villenet, C., Kerckaert, J.P., Lai, J.L., Preudhomme, C. & Roche-Lestienne, C. (2008) Cryptic and partial deletions of PRDM16 and RUNX1 without t(1;21)(p36;q22) and/or RUNX1-PRDM16 fusion in a case of progressive chronic myeloid leukemia: a complex chromosomal rearrangement of underestimated frequency in disease progression? Genes Chromosomes Cancer, 47, 1110-1117.
14. Du, Y., Jenkins, N.A. & Copeland, N.G. (2005) Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood, 106, 3932-3939.
15. Duhoux, F.P., Ameye, G., Lambot, V., Herens, C., Lambert, F., Raynaud, S., Wlodarska, I., Michaux, L., Roche-Lestienne, C., Labis, E., Taviaux, S., Chapiro, E., Nguyen Khac, F., Struski, S., Dobbelstein, S., Dastugue, N., Lippert, E., Speleman, F., Van Roy, N., De Weer, A., Rack, K., Talmant, P., Richebourg, S., Mugneret, F., Tigaud, I., Mozziconacci, M.J., Laibe, S., Nadal, N., Terré, C., Libouton, J.M., Decottignies, A., Vikkula, M. & Poirel, H.A. (2011) Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies. PLoS One, doi:10.1371/journal.pone.0026311.
16. Hazourli, S., Chagnon, P., Sauvageau, M., Fetni, R., Busque, L. & Hebert, J. (2006) Overexpression of PRDM16 in the presence and absence of the RUNX1/PRDM16 fusion gene in myeloid leukemias. Genes Chromosomes Cancer, 45, 1072-1076.
17. Horn, K.H., Warner, D.R., Pisano, M. & Greene, R.M. (2011) PRDM16 expression in the developing mouse embryo. Acta Histochemica, 113, 150-155.
18. Hosokawa, Y., Maeda, Y., Ichinohasama, R., Miura, I., Taniwaki, M. & Seto, M. (2000) The Ikaros gene, a central regulator of lymphoid differentiation, fuses to the BCL6 gene as a result of t(3;7)(q27;p12) translocation in a patient with diffuse large B-cell lymphoma. Blood, 95, 2719-2721.
19. International Standing Committee on Human Cytogenetic Nomenclature., Shaffer, L.G., Slovak, M.L. & Campbell, L.J. (2009) ISCN 2009: An International System for Human Cytogenetic Nomenclature (2009). Karger, Basel; Unionville, CT.
20. Jiang, G.L. & Huang, S. (2000) The yin-yang of PR-domain family genes in tumorigenesis. Histology and Histopathology, 15, 109-117.
21. Kajimura, S., Seale, P., Kubota, K., Lunsford, E., Frangioni, J.V., Gygi, S.P. & Spiegelman, B.M. (2009) Initiation of myoblast to brown fat switch by a PRDM16-C/EBP-beta transcriptional complex. Nature, 460, 1154-1158.
22. Kim, M., Lee, H.C., Tsedensodnom, O., Hartley, R., Lim, Y.S., Yu, E., Merle, P. & Wands, J.R. (2008) Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. Journal of Hepatology, 48, 780-791.
23. Lacy, P. (2005) The role of Rho GTPases and SNAREs in mediator release from granulocytes. Pharmacology and Therapeutics, 107, 358-376.
24. Lahortiga, I., Agirre, X., Belloni, E., Vazquez, I., Larrayoz, M.J., Gasparini, P., Lo Coco, F., Pelicci, P.G., Calasanz, M.J. & Odero, M.D. (2004) Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells. Oncogene, 23, 311-316.
25. Livak, K.J. & Schmittgen, T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-[Delta][Delta]CT Method. Methods, 25, 402-408.
26. Lugthart, S., Groschel, S., Beverloo, H.B., Kayser, S., Valk, P.J., van Zelderen-Bhola, S.L., Jan Ossenkoppele, G., Vellenga, E., van den Berg-de Ruiter, E., Schanz, U., Verhoef, G., Vandenberghe, P., Ferrant, A., Kohne, C.H., Pfreundschuh, M., Horst, H.A., Koller, E., von Lilienfeld-Toal, M., Bentz, M., Ganser, A., Schlegelberger, B., Jotterand, M., Krauter, J., Pabst, T., Theobald, M., Schlenk, R.F., Delwel, R., Dohner, K., Lowenberg, B. & Dohner, H. (2010) Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. Journal of Clinical Oncology, 28, 3890-3898.
27. Man, T.K., Lu, X.Y., Jaeweon, K., Perlaky, L., Harris, C.P., Shah, S., Ladanyi, M., Gorlick, R., Lau, C.C. & Rao, P.H. (2004) Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer, 4, 45.
28. Medves, S., Duhoux, F.P., Ferrant, A., Toffalini, F., Ameye, G., Libouton, J.M., Poirel, H.A. & Demoulin, J.B. (2010) KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia. Leukemia, 24, 1052-1055.
29. Mochizuki, N., Shimizu, S., Nagasawa, T., Tanaka, H., Taniwaki, M., Yokota, J. & Morishita, K. (2000) A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells. Blood, 96, 3209-3214.
30. Moir, D.J., Jones, P.A., Pearson, J., Duncan, J.R., Cook, P. & Buckle, V.J. (1984) A new translocation, t(1;3) (p36;q21), in myelodysplastic disorders. Blood, 64, 553-555.
31. Morishita, K., Parganas, E., William, C.L., Whittaker, M.H., Drabkin, H., Oval, J., Taetle, R., Valentine, M.B. & Ihle, J.N. (1992) Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. Proceedings of the National Academy of Sciences of the United States of America, 89, 3937-3941.
32. Mullighan, C.G., Goorha, S., Radtke, I., Miller, C.B., Coustan-Smith, E., Dalton, J.D., Girtman, K., Mathew, S., Ma, J., Pounds, S.B., Su, X., Pui, C.H., Relling, M.V., Evans, W.E., Shurtleff, S.A. & Downing, J.R. (2007) Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature, 446, 758-764.
33. Mullighan, C.G., Miller, C.B., Radtke, I., Phillips, L.A., Dalton, J., Ma, J., White, D., Hughes, T.P., Le Beau, M.M., Pui, C.H., Relling, M.V., Shurtleff, S.A. & Downing, J.R. (2008) BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature, 453, 110-114.
34. Mullighan, C.G., Su, X., Zhang, J., Radtke, I., Phillips, L.A., Miller, C.B., Ma, J., Liu, W., Cheng, C., Schulman, B.A., Harvey, R.C., Chen, I.M., Clifford, R.J., Carroll, W.L., Reaman, G., Bowman, W.P., Devidas, M., Gerhard, D.S., Yang, W., Relling, M.V., Shurtleff, S.A., Campana, D., Borowitz, M.J., Pui, C.H., Smith, M., Hunger, S.P., Willman, C.L. & Downing, J.R. (2009) Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. New England Journal of Medicine, 360, 470-480.
35. Nishikata, I., Sasaki, H., Iga, M., Tateno, Y., Imayoshi, S., Asou, N., Nakamura, T. & Morishita, K. (2003) A novel EVI1 gene family, MEL1, lacking a PR domain (MEL1S) is expressed mainly in t(1;3)(p36;q21)-positive AML and blocks G-CSF-induced myeloid differentiation. Blood, 102, 3323-3332.
36. Nucifora, G., Begy, C.R., Kobayashi, H., Roulston, D., Claxton, D., Pedersen-Bjergaard, J., Parganas, E., Ihle, J.N. & Rowley, J.D. (1994) Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations. Proceedings of the National Academy of Sciences of the United States of America, 91, 4004-4008.
37. Rippe, V., Drieschner, N., Meiboom, M., Murua Escobar, H., Bonk, U., Belge, G. & Bullerdiek, J. (2003) Identification of a gene rearranged by 2p21 aberrations in thyroid adenomas. Oncogene, 22, 6111-6114.
38. Roche-Lestienne, C., Deluche, L., Corm, S., Tigaud, I., Joha, S., Philippe, N., Geffroy, S., Lai, J.L., Nicolini, F.E. & Preudhomme, C. (2008) RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Blood, 111, 3735-3741.
39. Sakai, I., Tamura, T., Narumi, H., Uchida, N., Yakushijin, Y., Hato, T., Fujita, S. & Yasukawa, M. (2005) Novel RUNX1-PRDM16 fusion transcripts in a patient with acute myeloid leukemia showing t(1;21)(p36;q22). Genes Chromosomes Cancer, 44, 265-270.
40. Schneider, R., Bannister, A.J. & Kouzarides, T. (2002) Unsafe SETs: histone lysine methyltransferases and cancer. Trends in Biochemical Sciences, 27, 396-402.
41. Seale, P., Bjork, B., Yang, W., Kajimura, S., Chin, S., Kuang, S., Scime, A., Devarakonda, S., Conroe, H.M., Erdjument-Bromage, H., Tempst, P., Rudnicki, M.A., Beier, D.R. & Spiegelman, B.M. (2008) PRDM16 controls a brown fat/skeletal muscle switch. Nature, 454, 961-967.
42. Shimizu, S., Suzukawa, K., Kodera, T., Nagasawa, T., Abe, T., Taniwaki, M., Yagasaki, F., Tanaka, H., Fujisawa, S., Johansson, B., Ahlgren, T., Yokota, J. & Morishita, K. (2000) Identification of breakpoint cluster regions at 1p36.3 and 3q21 in hematologic malignancies with t(1;3)(p36;q21). Genes Chromosomes Cancer, 27, 229-238.
43. Shing, D.C., Trubia, M., Marchesi, F., Radaelli, E., Belloni, E., Tapinassi, C., Scanziani, E., Mecucci, C., Crescenzi, B., Lahortiga, I., Odero, M.D., Zardo, G., Gruszka, A., Minucci, S., Di Fiore, P.P. & Pelicci, P.G. (2007) Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice. Journal of Clinical Investigation, 117, 3696-3707.
44. Stevens-Kroef, M.J., Schoenmakers, E.F., van Kraaij, M., Huys, E., Vermeulen, S., van der Reijden, B. & van Kessel, A.G. (2006) Identification of truncated RUNX1 and RUNX1-PRDM16 fusion transcripts in a case of t(1;21)(p36;q22)-positive therapy-related AML. Leukemia, 20, 1187-1189.
45. Storlazzi, C.T., Albano, F., Guastadisegni, M.C., Impera, L., Muhlematter, D., Meyer-Monard, S., Wuillemin, W., Rocchi, M. & Jotterand, M. (2008) Upregulation of MEL1 and FLJ42875 genes by position effect resulting from a t(1;2)(p36;p21) occurring during evolution of chronic myelomonocytic leukemia. Blood Cells, Molecules, and Diseases, 40, 452-455.
46. Swerdlow, S.H. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer, Lyon, France.
47. Takahata, M., Inoue, Y., Tsuda, H., Imoto, I., Koinuma, D., Hayashi, M., Ichikura, T., Yamori, T., Nagasaki, K., Yoshida, M., Matsuoka, M., Morishita, K., Yuki, K., Hanyu, A., Miyazawa, K., Inazawa, J., Miyazono, K. & Imamura, T. (2009) SKI and MEL1 cooperate to inhibit transforming growth factor-beta signal in gastric cancer cells. J Biol Chem, 284, 3334-3344.
48. Tefferi, A. (2010) Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia, 24, 1128-1138.
49. Warner, D.R., Horn, K.H., Mudd, L., Webb, C.L., Greene, R.M. & Pisano, M.M. (2007) PRDM16/MEL1: a novel Smad binding protein expressed in murine embryonic orofacial tissue. Biochimica et Biophysica Acta, 1773, 814-820.
50. Xiao, Z., Zhang, M., Liu, X., Zhang, Y., Yang, L. & Hao, Y. (2006) MEL1S, not MEL1, is overexpressed in myelodysplastic syndromes patients with t(1;3)(p36;q21). Leukemia Research, 30, 332-334.
51. Xinh, P.T., Tri, N.K., Nagao, H., Nakazato, H., Taketazu, F., Fujisawa, S., Yagasaki, F., Chen, Y.Z., Hayashi, Y., Toyoda, A., Hattori, M., Sakaki, Y., Tokunaga, K. & Sato, Y. (2003) Breakpoints at 1p36.3 in three MDS/AML(M4) patients with t(1;3)(p36;q21) occur in the first intron and in the 5′ region of MEL1. Genes Chromosomes Cancer, 36, 313-316.
52. Yoshida, M., Nosaka, K., Yasunaga, J., Nishikata, I., Morishita, K. & Matsuoka, M. (2004) Aberrant expression of the MEL1S gene identified in association with hypomethylation in adult T-cell leukemia cells. Blood, 103, 2753-2760.
53. Zhao, C., Matveeva, E.A., Ren, Q. & Whiteheart, S.W. (2010) Dissecting the N-ethylmaleimide-sensitive factor: required elements of the N and D1 domains. J Biol Chem, 285, 761-772.